Found: 161
Select item for more details and to access through your institution.
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
- Published in:
- 2010
- By:
- Publication type:
- journal article
The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.
- Published in:
- Calcified Tissue International, 2023, v. 113, n. 4, p. 469, doi. 10.1007/s00223-023-01119-7
- By:
- Publication type:
- Article
Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.
- Published in:
- 2009
- By:
- Publication type:
- letter
Update on the association between non‐alcoholic fatty liver disease and Helicobacter pylori infection.
- Published in:
- International Journal of Clinical Practice, 2021, v. 75, n. 4, p. 1, doi. 10.1111/ijcp.13737
- By:
- Publication type:
- Article
Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1702, doi. 10.1111/dom.14774
- By:
- Publication type:
- Article
Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1805, doi. 10.1111/dom.12989
- By:
- Publication type:
- Article
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2010, v. 12, n. 5, p. 365, doi. 10.1111/j.1463-1326.2009.01176.x
- By:
- Publication type:
- Article
Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation.
- Published in:
- Rheumatology, 2015, v. 54, n. 5, p. 908, doi. 10.1093/rheumatology/keu425
- By:
- Publication type:
- Article
Comments to the Editor concerning the paper entitled "The microbiome and ophthalmic disease" by Baim et al.
- Published in:
- Experimental Biology & Medicine, 2019, v. 244, n. 6, p. 430, doi. 10.1177/1535370218824340
- By:
- Publication type:
- Article
Helicobacter Pylori and Insulin Resistance Association: Not Just a Myth, Not Yet a Fact.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐Year Clinical Trial.
- Published in:
- Journal of Bone & Mineral Research, 2019, v. 34, n. 12, p. 2220, doi. 10.1002/jbmr.3853
- By:
- Publication type:
- Article
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.
- Published in:
- Journal of Bone & Mineral Research, 2017, v. 32, n. 6, p. 1291, doi. 10.1002/jbmr.3110
- By:
- Publication type:
- Article
Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience.
- Published in:
- Pituitary, 2012, v. 15, n. 1, p. 25, doi. 10.1007/s11102-011-0303-6
- By:
- Publication type:
- Article
Comparative effects of sibutramine and orlistat on weight loss, glucose metabolism and leptin levels in non-diabetic obese patients: A prospective study.
- Published in:
- 2012
- By:
- Publication type:
- Letter
Relationship between Helicobacter pylori infection and autoimmune disorders.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2013, v. 51, n. 5, p. e73, doi. 10.1515/cclm-2012-0753
- By:
- Publication type:
- Article
A potential impact of Helicobacter pylori‐related sarcopenia on severity of portal hypertension.
- Published in:
- Liver International, 2021, v. 41, n. 5, p. 1168, doi. 10.1111/liv.14777
- By:
- Publication type:
- Article
Impact of Helicobacter pylori‐linked metabolic syndrome on non‐alcoholic fatty liver disease and its connected atrial fibrillation risk.
- Published in:
- Liver International, 2020, v. 40, n. 8, p. 2036, doi. 10.1111/liv.14488
- By:
- Publication type:
- Article
Influence of Helicobacter pylori‐connected metabolic syndrome on non‐alcoholic fatty liver disease and its related colorectal neoplasm high risk.
- Published in:
- Liver International, 2020, v. 40, n. 2, p. 475, doi. 10.1111/liv.14264
- By:
- Publication type:
- Article
CHAI and MACK‐3 as noninvasive indices for nonalcoholic steatohepatitis.
- Published in:
- Liver International, 2019, v. 39, n. 8, p. 1587, doi. 10.1111/liv.14123
- By:
- Publication type:
- Article
Helicobacter pylori-related chronic hepatitis C infection and the risk for cardiovascular disease.
- Published in:
- Liver International, 2017, v. 37, n. 7, p. 1082, doi. 10.1111/liv.13161
- By:
- Publication type:
- Article
Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
- Published in:
- Calcified Tissue International, 2021, v. 108, n. 5, p. 587, doi. 10.1007/s00223-020-00785-1
- By:
- Publication type:
- Article
Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?
- Published in:
- 2018
- By:
- Publication type:
- letter
No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response.
- Published in:
- Calcified Tissue International, 2011, v. 88, n. 5, p. 402, doi. 10.1007/s00223-011-9468-2
- By:
- Publication type:
- Article
Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis.
- Published in:
- 2010
- By:
- Publication type:
- Letter
Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
- Published in:
- European Journal of Endocrinology, 2018, v. 179, n. 1, p. R31, doi. 10.1530/EJE-18-0056
- By:
- Publication type:
- Article
Potential Impact of Active Helicobacter pylori Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality.
- Published in:
- Israel Medical Association Journal, 2018, v. 20, n. 11, p. 725
- By:
- Publication type:
- Article
Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone.
- Published in:
- Journal of Bone & Mineral Metabolism, 2010, v. 28, n. 1, p. 108
- By:
- Publication type:
- Article
Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Pagetâs disease of bone.
- Published in:
- Journal of Bone & Mineral Metabolism, 2008, v. 26, n. 6, p. 635, doi. 10.1007/s00774-008-0852-6
- By:
- Publication type:
- Article
Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease.
- Published in:
- Minerva Endocrinology, 2023, v. 48, n. 3, p. 346, doi. 10.23736/S2724-6507.21.03564-8
- By:
- Publication type:
- Article
Gastrointestinal and hepatobiliary disorders of patients from countries with low to middle income: a retrospective observational study in a Swiss emergency department.
- Published in:
- Archives of Medical Science. Civilization Diseases, 2021, v. 6, n. 1, p. e36, doi. 10.5114/amscd.2021.105524
- By:
- Publication type:
- Article
Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell Histiocytosis?
- Published in:
- 2012
- By:
- Publication type:
- Letter
GM‐CSF as a potential candidate of a vaccine‐induced reduction of Helicobacter pylori infection.
- Published in:
- Helicobacter, 2022, v. 27, n. 3, p. 1, doi. 10.1111/hel.12884
- By:
- Publication type:
- Article
Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy.
- Published in:
- Helicobacter, 2019, v. 24, n. 3, p. N.PAG, doi. 10.1111/hel.12588
- By:
- Publication type:
- Article
Impact of Helicobacter pylori and/or Helicobacter pylori‐related metabolic syndrome on gastroesophageal reflux disease‐ Barrett's esophagus‐ esophageal adenocarcinoma sequence.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Review: Impact of <italic>Helicobacter pylori</italic> on Alzheimer's disease: What do we know so far?
- Published in:
- Helicobacter, 2018, v. 23, n. 1, p. 1, doi. 10.1111/hel.12454
- By:
- Publication type:
- Article
Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B.
- Published in:
- Journal of Viral Hepatitis, 2023, v. 30, n. 8, p. 710, doi. 10.1111/jvh.13836
- By:
- Publication type:
- Article
Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 5, p. 660, doi. 10.1111/apt.18124
- By:
- Publication type:
- Article
Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 4, p. 540, doi. 10.1111/apt.18066
- By:
- Publication type:
- Article
Letter: Histological changes among asymptomatic chronic HBV carriers with normal alanine aminotransferase levels.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1252, doi. 10.1111/apt.17760
- By:
- Publication type:
- Article
higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 10, p. 1186, doi. 10.1111/apt.17484
- By:
- Publication type:
- Article
Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 54, n. 8, p. 1013, doi. 10.1111/apt.16575
- By:
- Publication type:
- Article
Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 11, p. 1215, doi. 10.1111/apt.15747
- By:
- Publication type:
- Article
Letter: Helicobacter pylori in proton pump inhibitor‐associated biliary disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 2, p. 313, doi. 10.1111/apt.15608
- By:
- Publication type:
- Article
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease.
- Published in:
- Therapeutics & Clinical Risk Management, 2023, v. 19, p. 77, doi. 10.2147/TCRM.S352008
- By:
- Publication type:
- Article
Impact of Helicobacter pylori Infection on Colon Oncogenesis.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2013, v. 108, n. 4, p. 625, doi. 10.1038/ajg.2013.17
- By:
- Publication type:
- Article
Impact of Helicobacter pylori and/or Helicobacter pylori–related metabolic syndrome on incidence of all‐cause and Alzheimer‧s dementia.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, n. 5, p. 723, doi. 10.1016/j.jalz.2019.01.008
- By:
- Publication type:
- Article